Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | MC3R | P41968 | 2/20 | 0.51 |
| ▸ | MC1R | Q01726 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13602533 | 0.90 | SMN1; SMN2 (0.49) | ALDH1A1HPGDSMN1; SMN2ITGB1ITGA4 | |
| SCHEMBL474618 | 0.88 | ACE (0.60) | ALDH1A1MC4RMC3RMC1RACE | |
| SCHEMBL474742 | 0.88 | ACE (0.60) | ALDH1A1MC4RMC3RMC1RACE | |
| SCHEMBL13602523 | 0.88 | ACE (0.44) | ALDH1A1HPGDGLAMC4RMC3R | |
| SCHEMBL5537821 | 0.88 | ACE (0.52) | ACE | |
| SCHEMBL5544828 | 0.88 | ACE (0.52) | ACE | |
| SCHEMBL28650436 | 0.87 | ACE (0.58) | ALDH1A1MC4RMC3RMC1RACE | |
| SCHEMBL13388251 | 0.86 | ALDH1A1 (0.50) | ALDH1A1HPGDGLAMC4RMC3R | |
| SCHEMBL13602459 | 0.86 | SMN1; SMN2 (0.48) | ALDH1A1HPGDACESMN1; SMN2ITGB1 | |
| SCHEMBL474918 | 0.85 | DPP4 (0.57) | ALDH1A1HPGDGLAMC4RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328865-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-2410844-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-9090661-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ALDH1A1 2400/4885HPGD 1852/4885GLA 3356/4885 |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | ALDH1A1 3778/4885HPGD 3682/4885GLA 3966/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | ALDH1A1 3778/4885HPGD 3682/4885GLA 3966/4885 |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ALDH1A1 2400/4885HPGD 1852/4885GLA 3356/4885 |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ALDH1A1 2400/4885HPGD 1852/4885GLA 3356/4885 |
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ALDH1A1 2400/4885HPGD 1852/4885GLA 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.